99,352 Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 86.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 214,777 shares of the company’s stock after acquiring an additional 99,352 shares during the period. Russell Investments Group Ltd. owned 0.33% of Protagonist Therapeutics worth $30,260,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PTGX. TFB Advisors LLC raised its stake in Protagonist Therapeutics by 3.0% in the third quarter. TFB Advisors LLC now owns 5,394 shares of the company’s stock valued at $760,000 after purchasing an additional 159 shares in the last quarter. GAMMA Investing LLC raised its stake in Protagonist Therapeutics by 7.2% during the second quarter. GAMMA Investing LLC now owns 3,109 shares of the company’s stock worth $381,000 after buying an additional 208 shares during the last quarter. Choreo LLC grew its stake in Protagonist Therapeutics by 9.3% during the third quarter. Choreo LLC now owns 2,533 shares of the company’s stock worth $357,000 after purchasing an additional 216 shares during the period. Keating Financial Advisory Services Inc. bought a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at $30,000. Finally, Parallel Advisors LLC boosted its stake in Protagonist Therapeutics by 205.9% during the third quarter. Parallel Advisors LLC now owns 361 shares of the company’s stock worth $51,000 after acquiring an additional 243 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Trading Down 4.7%

Protagonist Therapeutics stock opened at $124.83 on Tuesday. The business’s fifty day simple moving average is $139.88 and its two-hundred day simple moving average is $119.32. Protagonist Therapeutics, Inc. has a 12 month low of $77.00 and a 12 month high of $160.81. The company has a market capitalization of $8.15 billion, a price-to-earnings ratio of 26.45 and a beta of 1.21.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $3.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.57. Protagonist Therapeutics had a return on equity of 42.83% and a net margin of 62.04%. The business had revenue of $274.41 million for the quarter, compared to analysts’ expectations of $238.49 million. On average, equities research analysts predict that Protagonist Therapeutics, Inc. will post 5.52 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. The Goldman Sachs Group raised Protagonist Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $110.00 to $186.00 in a research report on Monday, August 10th. Wall Street Zen downgraded Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Wedbush reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, November 9th. HC Wainwright raised their target price on shares of Protagonist Therapeutics from $170.00 to $221.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Finally, Weiss Ratings raised shares of Protagonist Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating and sixteen have given a Buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $166.67.

View Our Latest Stock Analysis on Protagonist Therapeutics

Insider Buying and Selling at Protagonist Therapeutics

In related news, CFO Asif Ali sold 58,629 shares of Protagonist Therapeutics stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total value of $8,312,419.62. Following the completion of the sale, the chief financial officer owned 59,003 shares of the company’s stock, valued at $8,365,445.34. The trade was a 49.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinsesh Patel sold 63,548 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $146.18, for a total value of $9,289,446.64. Following the completion of the transaction, the chief executive officer directly owned 522,968 shares in the company, valued at $76,447,462.24. The trade was a 10.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 183,629 shares of company stock worth $26,552,987 over the last three months. Insiders own 5.19% of the company’s stock.

About Protagonist Therapeutics

(Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

See Also

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.